Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015

BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…

Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.

Authors: Eduardo Pérez-Gómez, Clara Andradas, Sandra Blasco-Benito, María M. Caffarel, et al
Journal of the National Cancer Institute, 8 April 2015

BACKGROUND: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS: We analyzed CB2 cannabinoid receptor protein expressio…

Proapoptotic effect of endocannabinoids in prostate cancer cells.

Authors: O. Orellana-Serradell, C. E. Poblete, C. Sanchez, E. A. Castellón, I. Gallegos, et al
Oncology Reports, April 2015

In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…

Phytocannabinoids and epilepsy

Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015

WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…

Cannabinoids in late‐onset Alzheimer’s disease

Authors: AIA Ahmed, MA van der Marck, GAH van den Elsen, MGM Olde Rikkert
Clinical Pharmacology & Therapeutics, 8 March 2015

Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing…

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Authors: Marta Di Forti, Arianna Marconi, Elena Carra, Sara Fraietta, Antonella Trotta, Matteo Bonomo, et al
The Lancet Psychiatry, March 2015

BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the associatio…

Synthetic and natural cannabinoids: the cardiovascular risk.

Authors: Ethan B. Russo
The British Journal of Cardiology, March 2015

Cannabis has been employed medicinally and recreationally for thousands of years, but it was not until the 1960s that the structure and pharmacology of its primary phytocannabinoid components, cannabidiol (CBD) and tetrahydrocannabinol (THC) were identified, and another genera…

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.

Authors: Jessica Margaret Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
International Reviews of Immunology, 2015

The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…

Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol.

Authors: Ruth Gallily, Zhannah Yekhtin, Lumír Ondřej Hanuš
Pharmacology & Pharmacy, 2015

Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-in- flammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was…

Successful authorised therapy of treatment resistant adult ADHD with Cannabis: experience from a medical practice with 30 patients

Authors: Eva Milz, Franjo Grotenhermen
Conference Poster, 2015

The medical certificates of 30 patients with adult ADHD, who were granted approval by the German Health Ministry to use cannabis flowers between 2012 and 2014, were analysed with regard to course of disease, previous treatment efforts, and effects of self-medi…

Medical marijuana laws and suicides by gender and age.

Authors: D. Mark Anderson, Daniel I. Rees, Joseph J. Sabia
American Journal of Public Health, December 2014

OBJECTIVES: We estimated the association between legalizing medical marijuana and suicides. METHODS:
We obtained state-level suicide data from the National Vital Statistics System’s Mortality Detail Files for 1990-2007. We used regression analysis to examine the association be…

TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation.

Authors: Michael J. Caterina
ACS Chemical Neuroscience, 19 November 2014

In the skin, cannabinoid lipids, whether of endogenous or exogenous origin, are capable of regulating numerous sensory, homeostatic, and inflammatory events. Although many of these effects are mediated by metabotropic cannabinoid receptors, a growing body of evidence has revea…